Skip to main content

Zeo ScientifiX, Inc.

corporate_fare Company Profile

Zeo ScientifiX, Inc.

ZEOX·OTC·Life Sciences·CIK 0001557376

We are a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics for degenerative diseases and regenerative medicine. We have a portfolio of proprietary products derived from ethically sourced birth tissue, including mesenchymal stem cells, stem cell and amniotic fluid derived exosomes, and Wharton's Jelly matrix. Our principal product is Zofin™, which is derived from amniotic fluid and manufactured to retain naturally occurring extracellular vesicles, proteins, and cell-secreted nanoparticles. We also manufacture Patient Pure X™ ("PPX™"), a proprietary autologous biologic containing a nanoparticle fraction precipitated from a patient's own peripheral blood. All of our products are manufactured in FDA-registered, cGMP-compliant laboratory facilities. Our portfolio of products ("RAAM Products") and related services are primarily used in the healthcare industry and administered through doctors and clinics ("Providers"). The state of Florida enacted a new "stem cell therapy" law, effective July 1, 2025 ("SB 1768"). This legislation authorizes licensed physicians to administer non-FDA-approved stem cell and other human tissue-derived therapies for orthopedic, wound care, and pain management indications. It mandates compliance with cGMP and prohibits the use of stem cells derived from aborted fetuses, promoting ethically sourced materials such as adult stem cells and umbilical cord blood. SB 1768 also requires informed patient consent and disclosure that treatments are not FDA-approved. We have begun to pursue clinical research and commercial sales strategies that comply with SB 1768.

Zeo ScientifiX, Inc. (OTC:ZEOX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for ZEOX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Zeo ScientifiX Awards Substantial Restricted Stock to CEO/CFO and CMO
  • Zeo ScientifiX Forms Strategic Partnership for U.S. Commercialization and Clinical Development of Stem Cell Therapy

Financial Snapshot

Fiscal year ended October 31, 2025
Revenue
$5.2M
Net Income
-$5.52M
Diluted EPS
-$0.86
Op. Cash Flow
-$718K
Free Cash Flow
-$741K
Gross Profit
$4.27M
Operating Income
-$5.39M
Cash & Equivalents
$221K
Total Debt
$243K
Debt / Equity
-0.17×
Net Margin
-106.2%
Shares Outstanding
6.75M sh
Source: 10-K · filed 2026-01-29 · accession 0001829126-26-000763
$0.84 +2.44% today
52-week range · as of 2026-10-26 $0.84 – $2.99
Market cap
$6.58M
Volume
4.6K (0.4× avg)
3-mo avg 11K
Live data · 2026-11-21 19:24 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ZEOX - Filings & News (Page 2)

ZEOX
Jan 21, 2026, 5:17 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $2.64
Real-time Price: $0.840 info
Change: -$1.80 (-68%) info
Market Cap: $6.583M info
ZEOX
Jan 07, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $2.88
Real-time Price: $0.840 info
Change: -$2.04 (-71%) info
Market Cap: $6.583M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets